A study to Assess the Effect of Fluvoxamine (CYP2C19 Inhibitor), Itraconazole (CYP3A4 Inhibitor) and Paroxetine (CYP2D6 Inhibitor) on the Pharmacokinetics of ASN51 in Healthy Subjects.

2023-508382-33-01 Protocol ASN51-104 Human pharmacology (Phase I) - Other Ended

Start 22 Feb 2024 · End 3 Jul 2024 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol ASN51-104

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 48
Countries 1
Sites 1

Proteinopathies

Key facts

Sponsor
Asceneuron S.A.
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Nervous System Diseases [C10]
Trial duration
22 Feb 2024 → 3 Jul 2024
Decision date (initial)
2024-02-20
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Proteinopathies

VersionLevelCodeTermSystem organ class
20.0 HLGT 10037008 Protein and amino acid metabolism disorders NEC 10027433

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Asceneuron S.A.

Sponsor organisation
Asceneuron S.A.
Address
Building B, Batiment Epfl Innovation Park Batiment Epfl Innovation Park
City
Lausanne
Postcode
1015
Country
Switzerland

Scientific contact point

Organisation
Asceneuron S.A.
Contact name
Head of Early Clinical Development

Public contact point

Organisation
Asceneuron S.A.
Contact name
Head of Early Clinical Development

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ended 48 1
Rest of world 0

Investigational sites

Netherlands

1 site · Ended
Pharmaceutical Research Associates Group B.V.
Early Clinical Services, Amerikaweg 18, 9407 TK, Assen

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2024-02-22 2024-07-03 2024-02-22

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-02-09 Netherlands Acceptable
2024-02-20
2024-02-20